Discuss the strategic deployment of European litigation venues for US pharma companies, including the UK High Court litigation, UPC proceedings and EPO oppositions, and compare the impacts on injunction risk, cost exposure, and global settlement dynamics.
Speaker(s):

Oliver Laing
Partner
Potter Clarkson

Mark Didmon
Partner
Potter & Clarkson
Agenda Track No.:
Track 3
Session Type:
Break / Networking
Force Inline Description:
0